Binding characteristics of pyrrole-scaffold hepatitis B virus capsid inhibitors and identification of novel potent compounds
This journal is © The Royal Society of Chemistry..
Hepatitis B virus (HBV) capsid assembly modulators (CAMs) are currently being evaluated in clinical trials as potential curative therapies for HBV. This study used in silico computational modeling to provide insights into the binding characteristics between the HBV core protein and two pyrrole-scaffold inhibitors, JNJ-6379 and GLP-26, both in the CAM-Normal (CAM-N) series. Molecular dynamics simulations showed that the pyrrole inhibitors displayed similar general binding-interaction patterns to NVR 3-778, another CAM-N, with hydrophobic interactions serving as the major driving force. However, consistent with their higher potency, the pyrrole inhibitors exhibited stronger nonpolar interactions with key residues in a solvent-accessible region as compared to NVR 3-778. This feature was facilitated by distinct hydrogen bond interactions of the pyrrole scaffold inhibitors with the residue 140 in chain B of the HBV core protein (L140B). Based on these findings, novel CAM-N compounds were designed to mimic the interaction with L140B residue while maximizing nonpolar interactions in the solvent-accessible region. Several 1H-pyrrole-2-carbonyl substituted pyrrolidine-based compounds with various hydrophobic side chains were synthesized and evaluated. Through analyses of the structure-activity and structure-druggability relations of a series of compounds, CU15 emerged as the most promising lead CAM-N compound, exhibiting sub-nanomolar potency and good pharmacokinetic profiles. Overall, the study demonstrated a practical approach to leverage computational methods for understanding key target binding features for rationale-based design, and for guiding the identification of novel compounds.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
RSC advances - 13(2023), 41 vom: 26. Sept., Seite 29004-29022 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruengsatra, Tanachote [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 18.10.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1039/d3ra04720b |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363011625 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363011625 | ||
| 003 | DE-627 | ||
| 005 | 20231226092436.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1039/d3ra04720b |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1209.xml |
| 035 | |a (DE-627)NLM363011625 | ||
| 035 | |a (NLM)37807973 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruengsatra, Tanachote |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Binding characteristics of pyrrole-scaffold hepatitis B virus capsid inhibitors and identification of novel potent compounds |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a This journal is © The Royal Society of Chemistry. | ||
| 520 | |a Hepatitis B virus (HBV) capsid assembly modulators (CAMs) are currently being evaluated in clinical trials as potential curative therapies for HBV. This study used in silico computational modeling to provide insights into the binding characteristics between the HBV core protein and two pyrrole-scaffold inhibitors, JNJ-6379 and GLP-26, both in the CAM-Normal (CAM-N) series. Molecular dynamics simulations showed that the pyrrole inhibitors displayed similar general binding-interaction patterns to NVR 3-778, another CAM-N, with hydrophobic interactions serving as the major driving force. However, consistent with their higher potency, the pyrrole inhibitors exhibited stronger nonpolar interactions with key residues in a solvent-accessible region as compared to NVR 3-778. This feature was facilitated by distinct hydrogen bond interactions of the pyrrole scaffold inhibitors with the residue 140 in chain B of the HBV core protein (L140B). Based on these findings, novel CAM-N compounds were designed to mimic the interaction with L140B residue while maximizing nonpolar interactions in the solvent-accessible region. Several 1H-pyrrole-2-carbonyl substituted pyrrolidine-based compounds with various hydrophobic side chains were synthesized and evaluated. Through analyses of the structure-activity and structure-druggability relations of a series of compounds, CU15 emerged as the most promising lead CAM-N compound, exhibiting sub-nanomolar potency and good pharmacokinetic profiles. Overall, the study demonstrated a practical approach to leverage computational methods for understanding key target binding features for rationale-based design, and for guiding the identification of novel compounds | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Meeprasert, Arthitaya |e verfasserin |4 aut | |
| 700 | 1 | |a Rattanangkool, Eakkaphon |e verfasserin |4 aut | |
| 700 | 1 | |a Deesiri, Sirikan |e verfasserin |4 aut | |
| 700 | 1 | |a Srisa, Jakkrit |e verfasserin |4 aut | |
| 700 | 1 | |a Udomnilobol, Udomsak |e verfasserin |4 aut | |
| 700 | 1 | |a Dunkoksung, Wilasinee |e verfasserin |4 aut | |
| 700 | 1 | |a Chuaypen, Natthaya |e verfasserin |4 aut | |
| 700 | 1 | |a Kiatbumrung, Rattanaporn |e verfasserin |4 aut | |
| 700 | 1 | |a Tangkijvanich, Pisit |e verfasserin |4 aut | |
| 700 | 1 | |a Vimolmangkang, Sornkanok |e verfasserin |4 aut | |
| 700 | 1 | |a Pudhom, Khanitha |e verfasserin |4 aut | |
| 700 | 1 | |a Prueksaritanont, Thomayant |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t RSC advances |d 2011 |g 13(2023), 41 vom: 26. Sept., Seite 29004-29022 |w (DE-627)NLM218315961 |x 2046-2069 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:41 |g day:26 |g month:09 |g pages:29004-29022 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1039/d3ra04720b |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 41 |b 26 |c 09 |h 29004-29022 | ||